Testing a reduced dose of the HPV vaccine
Treatments studied
Part of Infections clinical trials.
This study tests whether a single dose of the HPV vaccine is enough to protect against the viruses that cause several cancers. You will have the vaccine and some small tissue samples taken to see how your immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old
- You have never had an HPV vaccine
- Your body mass index (BMI) is under 35
- You are in good general health
- You are willing to have small samples taken from your lymph nodes and bone marrow
- You agree to skip the additional recommended HPV vaccine doses during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This trial tests a new vaccine called V540B that targets HPV, a common virus linked to certain cancers. The study aims to see if the vaccine is safe and produces a strong immune response in healthy people.
This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.